HLA-haploidentical allogeneic stem cell transplantation for refractory hematopoietic diseases

Not Applicable

Completed

• Conditions: Acute myeloid leukemia(AML) Acute lymphoblastic leukemia (ALL) Secondary acute myelogenous leukemia Chronic myeloid leukemia (CML) Myelodysplastic syndrome (MDS)

• Registration Number: JPRN-UMIN000002069
• Lead Sponsor: Hematology, Osaka City University, Graduate School of Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06-12
• Study Completion: 2015-02-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

Not provided

Exclusion Criteria

1) Major organ dysfunction a) Total bilirubin: >= 2.0mg/dl b) Serum creatinine: >= 2.0mg/dl c) Ejection fraction: < 50 % d) Pulmonary function test: %VC <40%, FEV1.0% <50% or SaO2 <90% on room air e) AST or ALT >= 3 x UNL 2) Uncontrolled active infection 3) Uncontrolled CNS invasion 4) Poorly controlled insulin-treated diabetes mellitus 5) Poorly controlled hypertension 6) Patients with a severe complication including heart failure, coronary failure, acute myocardial infarction within the last 3 months, liver cirrhosis and interstitial pneumonia 7) Pregnant, nursing or possible fertile woman 8) Patients with severe mental disorder who are likely to unable to participate in the study 9) A history of hypersensitivity or allergy to any drugs in conditioning regimen of this transplant 10) HIV antibody positivity 11) No indication for this study judged by physician in charge. (Note: HBs antigen positivity and HCV antibody positivity is not excluded.)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Engraftment rate